have demonstrated that the combination of the CXCR4 antagonist LY2510924 and the FLT3 inhibitor quizartinib reversed the stroma-mediated resistance against the FLT3 inhibitor and induced the mobilization and differentiation of AML cells in mice, resulting in enhanced anti-leukemia effects (32). Here, CXCR4 is linked to leukemia.